HUTCHMED Reports Positive Phase II Results for Cholangiocarcinoma Treatment

HUTCHMED announced favorable outcomes from its Phase II study of fanregratinib, a drug targeting advanced intrahepatic cholangiocarcinoma. The trial achieved its primary goal with a 42.5% objective response rate, indicating effective and sustained disease control. These findings are slated for presentation at an upcoming congress and support a priority review for a New Drug Application in China.